Back

Analysis of the effect of specific therapy on exercise capacity in patients with anderson-fabry disease

29 August 2026 (16:05 - 16:15)
Organised by: Logo
Congress Presentation Part of: Cardiovascular pharmacotherapy in advanced kidney disease: efficacy, safety, and outcomes Renal Failure and Cardiovascular Disease ESC Professional Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Alessandra Cuomo

University of Naples Federico II, Naples (Italy)

4 More presentations in this session

Presentation thumbnail
Effect of dapagliflozin on left ventricular mass in patients with kidney failure receiving maintenance hemodialysis: Primary results from the DAPA-HD trial
Associate Professor T. Zelniker (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Nanoformulated omega-3-rich linseed oil reverses ex vivo the phenotype of monocytes of hemodialysis patients from a pro into an anti-inflammatory one with attenuated ROS formation and cell activation
Doctor G. Lima (Strasbourg, FR)
Abstract Slides Video
Presentation thumbnail
Omega-3 fatty acid supplementation and major cardiovascular events in maintenance haemodialysis: Systematic review and meta-analysis including PISCES
Doctor M. Egaimi (Ras al Khaimah, AE)
Abstract Slides Video
Presentation thumbnail
Real-world effectiveness and safety of finerenone in patients with chronic kidney disease and type 2 diabetes in the United States: A FOUNTAIN platform analysis
Doctor S. Rao (Durham, US)
Abstract Slides Video

Access the full session

Session thumbnail
Cardiovascular pharmacotherapy in advanced kidney disease: efficacy, safety, and outcomes
Video

The Event

Event poster

ESC Congress 2026

29 August 2026 16:05 CET
You may be interested in
thumbnail
Congress Presentation
Changes in peak oxygen consumption on excercise and cardiomyopathy disease stage in Fabry disease
1 September 2024
thumbnail
Congress Session
Nature Medicine: 2025 highlights
31 August 2025
thumbnail
Congress Presentation
Cardiac red flags in Fabry disease: early conduction disease despite long-term enzyme replacement therapy.
29 August 2026
thumbnail
Congress Presentation
Long-term clinical-pathologic results of enzyme replacement therapy in pre-hypertrophic fabry disease cardiomyopathy.
2 September 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources